Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundat...
-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
Beghou announces the Beghou Arc Platform, a flexible, connected commercialization platform designed to help life sciences teams overcome data overload, r...
Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO) and InnoCare Pharma Limited (&ldqu...
The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...
DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...
Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that...
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fas...
POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mos...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...
ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 mil...
Global pharma major Lupin Limited (Lupin), announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisi...
New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...
© 2025 Biopharma Boardroom. All Rights Reserved.
